Gene · 64006
Papers4,423
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
921 to 940 of 4,423
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New Anti-Flavivirus Fusion Loop Human Antibodies with Zika Virus-Neutralizing Potential. | Int J Mol Sci | 2022 | 35887153 | PubTator, text mining | PubMed |
| Can Modern Molecular Modeling Methods Help Find the Area of Potential Vulnerability of Flaviviruses? | Int J Mol Sci | 2022 | 35887069 | PubTator, text mining | PubMed |
| Predicting Antigenic Peptides from Rocio Virus NS1 Protein for Immunodiagnostic Testing Using Immunoinformatics and Molecular Dynamics Simulation. | Int J Mol Sci | 2022 | 35887029 | PubTator, text mining | PubMed |
| Highly Sensitive Flexible SERS-Based Sensing Platform for Detection of COVID-19. | Biosensors (Basel) | 2022 | 35884269 | PubTator, text mining | PubMed |
| Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches. | Biomolecules | 2022 | 35883527 | PubTator, text mining | PubMed |
| Seronegative Myasthenia Gravis with Concomitant SARS-CoV-2 Infection in a Dog. | Vet Sci | 2022 | 35878335 | PubTator, text mining | PubMed |
| Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study. | Curr Issues Mol Biol | 2022 | 35877432 | PubTator, text mining | PubMed |
| Recipients of COVID-19 vaccines face challenges of SARS-CoV-2 variants. | Int J Biol Sci | 2022 | 35874950 | PubTator, text mining | PubMed |
| Vitamin C and its therapeutic potential in the management of COVID19. | Clin Nutr ESPEN | 2022 | 35871955 | PubTator, text mining | PubMed |
| Does COVID-19 lockdowns have impacted on global dengue burden? A special focus to India. | BMC Public Health | 2022 | 35869470 | PubTator, text mining | PubMed |
| Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera. | Sci Rep | 2022 | 35864211 | PubTator, text mining | PubMed |
| Pathogenic Mechanism and Multi-omics Analysis of Oral Manifestations in COVID-19. | Front Immunol | 2022 | 35860279 | PubTator, text mining | PubMed |
| Inhibiting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants: Targeting the Spike and Envelope Proteins Using Nanomaterial Like Peptides. | J Biomed Nanotechnol | 2022 | 35854452 | PubTator, text mining | PubMed |
| DDX5: an expectable treater for viral infection- a literature review. | Ann Transl Med | 2022 | 35845539 | PubTator, text mining | PubMed |
| Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein. | Bioessays | 2022 | 35843871 | PubTator, text mining | PubMed |
| SARS-CoV-2 and the central nervous system: Emerging insights into hemorrhage-associated neurological consequences and therapeutic considerations. | Ageing Res Rev | 2022 | 35843590 | PubTator, text mining | PubMed |
| Toehold-controlled ligation and transcription for accurate COVID-19 genotyping. | Anal Biochem | 2022 | 35843299 | PubTator, text mining | PubMed |
| Pre-clinic study of radiopharmaceutical for Covid-19 inactivation: Dose distribution with Monte Carlo Simulation. | Appl Radiat Isot | 2022 | 35839712 | PubTator, text mining | PubMed |
| A comprehensive genomic study, mutation screening, phylogenetic and statistical analysis of SARS-CoV-2 and its variant omicron among different countries. | J Infect Public Health | 2022 | 35839568 | PubTator, text mining | PubMed |
| Interaction of Bioactive Compounds of Moringa oleifera Leaves with SARS-CoV-2 Proteins to Combat COVID-19 Pathogenesis: a Phytochemical and In Silico Analysis. | Appl Biochem Biotechnol | 2022 | 35838886 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64006/papers?page=47